IRLAB: Invitation to the interim report for Q3 2023 presentation and webcast

October 19, 2023

Gothenburg, Sweden, October 19, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-September 2023. The interim report and presentation will be published on Wednesday, October 25 at 07:00 CEST.

Gothenburg, Sweden, October 19, 2023 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January-September 2023. The interim report and presentation will be published on Wednesday, October 25 at 07:00 CEST.

The presentation will be held on October 25, 2023, at 10:00 CEST via digital webcast. Gunnar Olsson, CEO, Nicholas Waters, EVP and Head of R&D, and Viktor Siewertz, CFO, will comment the interim report for the period January-September 2023. The presentation will be held in English and followed by a Q&A session.

Follow the webcast online: https://youtube.com/live/6D1RmKaQ6dc

The interim report and the presentation will be available on www.irlab.se, and the recorded version of the presentation will be available shortly afterward.

For more information

Gunnar Olsson, CEO
Phone: +46 70 576 14 02
E-mail: gunnar.olsson@irlab.se

Viktor Siewertz, CFO
Phone: +46 727 10 70 70
E-mail: viktor.siewertz@irlab.se

About IRLAB

IRLAB is discovering and developing a portfolio of transformative therapies targeting all stages of Parkinson’s disease. The company has its origin in Nobel Laureate Prof. Arvid Carlsson’s research group and the discovery of a connection between the brain’s neurotransmitters and CNS disorders. Mesdopetam (IRL790), in development for the treatment of levodopa-induced dyskinesias, has completed Phase IIb and is in preparation toward Phase III. Pirepemat (IRL752), is currently in Phase IIb, being evaluated for its effect on balance and fall frequency in Parkinson’s disease. In addition, the company is also progressing the three preclinical programs IRL942, IRL757, and IRL1117 towards Phase I studies. The pipeline is driven by IRLAB’s proprietary systems biology-based Integrative Screening Process (ISP) research platform. Headquartered in Sweden, IRLAB is listed on Nasdaq Stockholm (IRLAB A). For more information, please visit www.irlab.se.

Attachments

IRLAB: Invitation to the interim report for Q3 2023 presentation and webcast

Documents & Links